Astrazeneca plc - ADR
AZN
Market Cap$243.45B
Close$
Earnings Call Q2 2024
July 25, 2024 - AI Summary
AstraZeneca reported strong financial results for the first half of 2024, with total revenue growing by 18% and a record second quarter revenue of almost $13 billion.
The company upgraded its full-year guidance, now expecting both total revenue and core EPS to increase by mid-teens percentages, driven by the underlying strength of its business.
Oncology, biopharmaceuticals, and rare disease all delivered double-digit growth in the first half, supported by increasing demand for key medicines such as Tagrisso, Calquence, Imfinzi, Lynparza, and Farxiga.
Exclusive for Stockcircle Pro members
Sign up
$120.81
50% upside
Current Fair Value
50% upsideUndervalued by 50% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $243.45 Billion |
|---|---|
| Enterprise Value | $270.65 Billion |
| Dividend Yield | $1.436 (1.83%) |
| Earnings per Share | $2.03 |
| Beta | 0.47 |
| Outstanding Shares | 3,100,536,150 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 38.46 |
|---|---|
| PEG | 619.23 |
| Price to Sales | 5.37 |
| Price to Book Ratio | 6.71 |
| Enterprise Value to Revenue | 5.48 |
| Enterprise Value to EBIT | 28.67 |
| Enterprise Value to Net Income | 42 |
| Total Debt to Enterprise | 0.13 |
| Debt to Equity | 0.86 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About AstraZeneca Plc
CEO: Pascal Soriot AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respira...